CER Daily Newsfeed

Value Viewpoint: December 6, 2024

(12/6, Kimberly Westrich, LinkedIn) comments “...New research from my colleague, NPC Chief Science Officer Jon Campbell, published in algorithms this week seeks to understand the differences in modeling approaches used in cost-effectiveness analysis. In the study, Jon and his co-authors compared cohort and patient-level modeling techniques for a hypothetical neurological disease and found that there were similar base case results.” Full

Biden Administration’s Access Model Offers Hope For Cell And Gene Therapies

(12/7, Joshua P. Cohen, Forbes.com) reports “...The Biden Administration announced this week that the manufacturers of Lyfgenia and Casgevy have entered into agreements with the Centers for Medicare and Medicaid Services to participate in the Cell and Gene Therapy Access Model, which allows CMS to negotiate outcomes-based agreements on behalf of state Medicaid programs for cell and gene therapies, beginning with sickle cell disease treatments. If successful, this could serve as a blueprint for other cell and gene therapies that have faced considerable barriers with respect to patient access.” Full

How Mayo Clinic Is Using Real-World Data to Advance Precision Medicine

(12/9, Andrea Fox, Healthcare IT News) reports “...Where ChatGPT and Google Gemini may only produce relevant, evidence-based answers in healthcare a fraction of the time, California-based Atropos Health said its federated healthcare data network can offer healthcare users a detailed, accurate consultation to even the most obscure medical questions because it's based only on peer-reviewed, real-world data.” Full

How AI Can Close the Gap in Evidence-Based Care

(12/9, Brigham Hyde, MedCity News) comments “...One of the biggest obstacles to evidence generation is the tedious analysis of medical records and the lengthy de-identification process. Generative AI exists to automate impending tasks, one of which is producing real-world evidence. AI can expedite this time-consuming process and provide researchers and clinicians with deidentified data that fills gaps in representation. These data sets can then be compiled and used to fuel large-language models (LLMs) with more accurate, research-grade evidence or supplement missing data for clinical decision-making, ensuring more research is available for minority populations.” Full

EMA Homes In On How To Improve RWD Quality

(12/9, Neena Brizmohun, Pink Sheet) reports “...The European Medicines Agency is seeking feedback on draft guidance that aims to provide ‘actionable and focused recommendations’ for assessing and improving the quality of real-world data (RWD) for regulatory use.” Subscription Required